How many insider trades does FilingIQ track for NAMS?

FilingIQ tracks 200 Form 4 insider transactions for NAMS (NewAmsterdam Pharma Co N.V.), covering filings from Feb 13, 2024 onwards. 23 of those were filed in the last 90 days.

Are NAMS insiders net buyers or net sellers?

Across the full Form 4 history for NAMS, 13 transactions (7%) were open-market purchases and 90 (45%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does NAMS insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is NAMS in?

NewAmsterdam Pharma Co N.V. (NAMS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $4.14B.

NAMS insider trading

NasdaqGM Healthcare

NewAmsterdam Pharma Co N.V. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

200

Last 90 days

Buys / sells

7% / 45%

Market cap

$4.14B

About NewAmsterdam Pharma Co N.V.

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Company website: www.newamsterdampharma.com

NAMS insider activity at a glance

FilingIQ has scored 200 insider transactions for NAMS since Feb 13, 2024. The most recent filing in our index is dated Mar 11, 2026.

Across the full history, 13 open-market purchases and 90 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on NAMS insider trades is 61.1/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live NAMS trades on FilingIQ Raw filings on SEC EDGAR

Latest NAMS Form 4 filings

Davidson Michael H. Chief Executive Officer

S Mar 2, 2026

Davidson Michael H. Chief Executive Officer

S Mar 26, 2025

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for NAMS?: FilingIQ tracks 200 Form 4 insider transactions for NAMS (NewAmsterdam Pharma Co N.V.), covering filings from Feb 13, 2024 onwards. 23 of those were filed in the last 90 days.
Are NAMS insiders net buyers or net sellers?: Across the full Form 4 history for NAMS, 13 transactions (7%) were open-market purchases and 90 (45%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does NAMS insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is NAMS in?: NewAmsterdam Pharma Co N.V. (NAMS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $4.14B.

Methodology & sources

Every NAMS insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.